"Hypothesis: Paroxetine, a G Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor Reduces Morbidity and Mortality in Patients With Heart Failure." by Jonathan M. Powell

Selected Works of Steven Borzak, MD, FACC

Article

Hypothesis: Paroxetine, a G Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor Reduces Morbidity and Mortality in Patients With Heart Failure.

Journal of Cardiovascular Pharmacology and Therapeutics (2017)

Jonathan M. Powell, Florida Atlantic University
Emanuel Ebin, Florida Atlantic University
Steven Borzak, Florida Atlantic University
Anastasios Lymperopoulos, Nova Southeastern University
Charles H. Hennekens, Florida Atlantic University

Link

Disciplines

Medicine and Health Sciences,
Anesthesiology,
Cardiology and
Internal Medicine

Publication Date

January 1, 2017

DOI

10.1177/1074248416644350

Citation Information

Jonathan M. Powell, Emanuel Ebin, Steven Borzak, Anastasios Lymperopoulos, et al.. "Hypothesis: Paroxetine, a G Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor Reduces Morbidity and Mortality in Patients With Heart Failure." Journal of Cardiovascular Pharmacology and Therapeutics Vol. 22 Iss. 1 (2017) p. 51 - 53
Available at: http://works.bepress.com/steven-borzak/20/